Patients with interstitial lung diseases face an unpredictable journey. Working closely with Evoke Group we produced a series videos that looks at Boehringer Ingelheim commitment to scientific research. The Inbuild clinical trial is the first and largest phase III global trial to include patients across the broad spectrum of ILDs that develop the ‘progressive fibrosing phenotype’, into a single trial.
